ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma Read more
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer Read more